These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17601558)

  • 1. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies.
    Zhang H; Shi YG; Woods JH; Watson SJ; Ko MC
    Eur J Pharmacol; 2007 Sep; 570(1-3):89-96. PubMed ID: 17601558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects.
    Zhang H; Torregrossa MM; Jutkiewicz EM; Shi YG; Rice KC; Woods JH; Watson SJ; Ko MC
    Eur J Neurosci; 2006 Feb; 23(4):984-94. PubMed ID: 16519663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats.
    Torregrossa MM; Isgor C; Folk JE; Rice KC; Watson SJ; Woods JH
    Neuropsychopharmacology; 2004 Apr; 29(4):649-59. PubMed ID: 14647482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.
    Torregrossa MM; Jutkiewicz EM; Mosberg HI; Balboni G; Watson SJ; Woods JH
    Brain Res; 2006 Jan; 1069(1):172-81. PubMed ID: 16364263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats.
    Torregrossa MM; Folk JE; Rice KC; Watson SJ; Woods JH
    Psychopharmacology (Berl); 2005 Nov; 183(1):31-40. PubMed ID: 16220339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.
    Jutkiewicz EM; Torregrossa MM; Sobczyk-Kojiro K; Mosberg HI; Folk JE; Rice KC; Watson SJ; Woods JH
    Eur J Pharmacol; 2006 Feb; 531(1-3):151-9. PubMed ID: 16442521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.
    Mague SD; Pliakas AM; Todtenkopf MS; Tomasiewicz HC; Zhang Y; Stevens WC; Jones RM; Portoghese PS; Carlezon WA
    J Pharmacol Exp Ther; 2003 Apr; 305(1):323-30. PubMed ID: 12649385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.
    Beardsley PM; Howard JL; Shelton KL; Carroll FI
    Psychopharmacology (Berl); 2005 Nov; 183(1):118-26. PubMed ID: 16184376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa-opioid receptors mediate the antidepressant-like activity of hesperidin in the mouse forced swimming test.
    Filho CB; Del Fabbro L; de Gomes MG; Goes AT; Souza LC; Boeira SP; Jesse CR
    Eur J Pharmacol; 2013 Jan; 698(1-3):286-91. PubMed ID: 23178563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel κ agonist and μ partial agonist, in mice.
    Wang Q; Long Y; Hang A; Zan GY; Shu XH; Wang YJ; Liu JG
    Psychopharmacology (Berl); 2016 Jun; 233(12):2411-8. PubMed ID: 27113225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.
    McLaughlin JP; Marton-Popovici M; Chavkin C
    J Neurosci; 2003 Jul; 23(13):5674-83. PubMed ID: 12843270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test.
    Huang P; Tunis J; Parry C; Tallarida R; Liu-Chen LY
    Eur J Pharmacol; 2016 Jun; 781():53-9. PubMed ID: 27044434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model.
    Russo-Neustadt A; Ha T; Ramirez R; Kesslak JP
    Behav Brain Res; 2001 Apr; 120(1):87-95. PubMed ID: 11173088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of mu and kappa opioid antagonists on Fos-like immunoreactivity in extended amygdala.
    Carr KD; Kutchukhidze N; Park TH
    Brain Res; 1999 Mar; 822(1-2):34-42. PubMed ID: 10082881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
    Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M
    Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
    Burke NN; Ferdousi M; Deaver DR; Finn DP; Roche M; Kelly JP
    Neuropharmacology; 2019 Mar; 146():327-336. PubMed ID: 30553825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dynamic relationship between mu and kappa opioid receptors in body temperature regulation.
    Chen X; McClatchy DB; Geller EB; Tallarida RJ; Adler MW
    Life Sci; 2005 Dec; 78(4):329-33. PubMed ID: 16257420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral changes after maternal separation are reversed by chronic constant light treatment.
    Dimatelis JJ; Stein DJ; Russell VA
    Brain Res; 2012 Oct; 1480():61-71. PubMed ID: 22975437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.
    Makino M; Kitano Y; Komiyama C; Hirohashi M; Takasuna K
    Br J Pharmacol; 2000 Jul; 130(6):1269-74. PubMed ID: 10903965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.